CRISPR Therapeutics AG Stock Price and Value Analysis

Should you buy CRISPR Therapeutics AG stock? (NASDAQ:CRSP). Let's see how it does in our automated value investing analysis system.

CRSP Free Cash Flow Trend

Free Cash Flow trendline for CRSP
Free Cash Flow trendline for CRISPR Therapeutics AG

Hmm, we can't give any reliable projection for CRISPR Therapeutics AG's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has stable growth.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the CRSP Numbers

CRSP Price
(CRISPR Therapeutics AG stock price per share)
[?] PE Ratio versus Sector 385% higher than other Healthcare stocks
[?] PE Ratio versus Industry 70% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 19%

Is CRISPR Therapeutics AG Stock on Sale?

Based on our analysis, we believe that you should not buy CRISPR Therapeutics AG right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CRSP Stock?

Does CRISPR Therapeutics AG have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.